MA63064B1 - Anticorps anti-tmprss6 et leurs utilisations - Google Patents

Anticorps anti-tmprss6 et leurs utilisations

Info

Publication number
MA63064B1
MA63064B1 MA63064A MA63064A MA63064B1 MA 63064 B1 MA63064 B1 MA 63064B1 MA 63064 A MA63064 A MA 63064A MA 63064 A MA63064 A MA 63064A MA 63064 B1 MA63064 B1 MA 63064B1
Authority
MA
Morocco
Prior art keywords
antibodies
tmprss6
bind
disorder
humans
Prior art date
Application number
MA63064A
Other languages
English (en)
French (fr)
Other versions
MA63064A1 (fr
Inventor
Andrew J. Murphy
William Olson
Sarah J. Hatsell
Harvey CHIN
Heinrich Emil LOB
Kei SAOTOME
Bojie ZHANG
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of MA63064A1 publication Critical patent/MA63064A1/fr
Publication of MA63064B1 publication Critical patent/MA63064B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA63064A 2021-05-11 2022-05-10 Anticorps anti-tmprss6 et leurs utilisations MA63064B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163187150P 2021-05-11 2021-05-11
PCT/US2022/028595 WO2022240877A1 (en) 2021-05-11 2022-05-10 Anti-tmprss6 antibodies and uses thereof

Publications (2)

Publication Number Publication Date
MA63064A1 MA63064A1 (fr) 2024-02-29
MA63064B1 true MA63064B1 (fr) 2025-02-28

Family

ID=81927373

Family Applications (1)

Application Number Title Priority Date Filing Date
MA63064A MA63064B1 (fr) 2021-05-11 2022-05-10 Anticorps anti-tmprss6 et leurs utilisations

Country Status (14)

Country Link
US (2) US12448435B2 (enExample)
EP (1) EP4337695A1 (enExample)
JP (1) JP2024517931A (enExample)
KR (1) KR20240005894A (enExample)
CN (1) CN117730099A (enExample)
AU (1) AU2022274888A1 (enExample)
BR (1) BR112023023558A2 (enExample)
CA (1) CA3218455A1 (enExample)
CL (1) CL2023003331A1 (enExample)
CO (1) CO2023016777A2 (enExample)
IL (1) IL308375A (enExample)
MA (1) MA63064B1 (enExample)
MX (1) MX2023013248A (enExample)
WO (1) WO2022240877A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022240877A1 (en) 2021-05-11 2022-11-17 Regeneron Pharmaceuticals, Inc. Anti-tmprss6 antibodies and uses thereof
WO2024211404A2 (en) * 2023-04-04 2024-10-10 Disc Medicine, Inc. Anti-tmprss6 antibodies and uses thereof
WO2025245434A1 (en) * 2024-05-24 2025-11-27 Disc Medicine, Inc. Compositions and methods for treating myelodysplastic syndromes (mds)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
GB0916576D0 (en) * 2009-09-22 2009-10-28 Malmsten Nils M Polypeptides and uses thereof
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
CA2991637C (en) 2015-07-31 2022-07-05 Medimmune Limited Methods for treating hepcidin-mediated disorders
KR20220107252A (ko) * 2019-11-29 2022-08-02 키맵 리미티드 생리학적 철분 과다에 대한 치료
CN115243762A (zh) * 2020-04-07 2022-10-25 迈威(美国)生物治疗有限公司 抗tmprss6抗体及其用途
WO2022240877A1 (en) 2021-05-11 2022-11-17 Regeneron Pharmaceuticals, Inc. Anti-tmprss6 antibodies and uses thereof

Also Published As

Publication number Publication date
JP2024517931A (ja) 2024-04-23
MX2023013248A (es) 2024-01-29
US20220411487A1 (en) 2022-12-29
BR112023023558A2 (pt) 2024-03-12
MA63064A1 (fr) 2024-02-29
IL308375A (en) 2024-01-01
CN117730099A (zh) 2024-03-19
AU2022274888A1 (en) 2023-12-07
US12448435B2 (en) 2025-10-21
CO2023016777A2 (es) 2023-12-11
EP4337695A1 (en) 2024-03-20
CA3218455A1 (en) 2022-11-17
US20260098084A1 (en) 2026-04-09
KR20240005894A (ko) 2024-01-12
WO2022240877A1 (en) 2022-11-17
CL2023003331A1 (es) 2024-06-07

Similar Documents

Publication Publication Date Title
MA63064B1 (fr) Anticorps anti-tmprss6 et leurs utilisations
MA54405B1 (fr) Anticorps de la glycoprotéine de spicule anti-sras-cov-2 et fragments de liaison à l'antigène
MA32566B1 (fr) Anticorps neutralisant les cytomégalovirus humains et leurs utilisations
WO2003106498A3 (en) Ox40 (=cd134) receptor agonistic and therapeutic use
MA31225B1 (fr) Anticorps neutralisants des cytomegalovirus humains et leur utilisation
MA32577B1 (fr) Anticorps neutralisants le virus de l'influenza a et leurs utilisations
MA46619B1 (fr) Anticorps anti-il-33 et leurs utilisations
MA32561B1 (fr) Anticorps neutralisant le cytomegalovirus humain et leurs utilisations
MA30353B1 (fr) Anticorps se liant à la protéine tyrosine phosphatase bêta humaine (hptpbêta) et utilisations correspondantes.
MA37761A1 (fr) Protéines de liaison à un antigène antagoniste d'un double récepteur et leurs utilisations
MA31634B1 (fr) Anticorps humains en cd20 humain et leur procede d'utilisation
US4849352A (en) Antibody purification process
MA53689B1 (fr) Anticorps humanisés contre un fragment bêta d'une chaîne de la famille 9 du récepteur cellulaire trbv-9 de l'humain et méthodes de leur application
MA53688A1 (fr) Anticorps monoclonaux qui se lient spécifiquement à trbv-9 de l'humain
EP4157885A4 (en) Anti-cldn18.2 antibodies and diagnostic uses thereof
EP4112722A4 (en) VIM-TYPE CARBAPENEMASE-RESISTANT HYBRIDOMA CELL LINE, MONOCLONAL ANTIBODY (MAB) AND USE THEREOF
EP4265717A4 (en) Mouse anti-mcr-1/mcr-2 protein hybridoma cell strain, monoclonal antibody and use
CA3156096A1 (en) Pd1 and vegfr2 dual-binding agents
MA61946B1 (fr) Anticorps capables de se lier à la protéine spike du coronavirus sars-cov-2
BR0314369A (pt) Métodos para inibir o crescimento de uma célula, para induzir morte celular de uma célula de câncer, para tratar ou prevenir câncer em um indivìduo e para identificar um agente que inibe o crescimento canceroso de uma célula, agente, e, anticorpo ephb4 purificado
ATE174967T1 (de) Monoklonale antikörper gegen glykoprotein p
WO2003105753A3 (en) METHODS AND COMPOSITIONS FOR GRAFTING FUNCTIONAL LOOPS INTO A PROTEIN
CL2025002112A1 (es) Anticuerpo anti-npr1; método de producción; y su uso.
WO2019246176A8 (en) Anti-factor xii/xiia antibodies and uses thereof
PT1042492E (pt) Anticorpos monoclonais humanizados que protegem contra doença induzida pela toxina shiga